4//SEC Filing
Secora Michael 4
Accession 0001601830-24-000204
CIK 0001601830other
Filed
Nov 13, 7:00 PM ET
Accepted
Nov 14, 7:19 PM ET
Size
21.4 KB
Accession
0001601830-24-000204
Insider Transaction Report
Form 4
Secora Michael
Chief Financial Officer
Transactions
- Exercise/Conversion
Class A Common Stock
2024-11-12$2.22/sh+39,375$87,413→ 1,490,256 total - Sale
Class A Common Stock
2024-11-12$7.64/sh−15,000$114,629→ 1,475,256 total - Sale
Class A Common Stock
2024-11-13$7.66/sh−15,000$114,876→ 1,499,631 total - Exercise/Conversion
Class A Common Stock
2024-11-13$2.22/sh+39,375$87,413→ 1,514,631 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-11-12−39,375→ 377,010 totalExercise: $2.22Exp: 2030-03-03→ Class A Common Stock (39,375 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-11-13−39,375→ 337,635 totalExercise: $2.22Exp: 2030-03-03→ Class A Common Stock (39,375 underlying)
Holdings
- 685,177
Stock Option (Right to Buy)
Exercise: $2.22Exp: 2030-03-03→ Class A Common Stock (0 underlying) - 116,684
Stock Option (Right to Buy)
Exercise: $11.40Exp: 2032-02-04→ Class A Common Stock (0 underlying) - 404,857
Stock Option (Right to Buy)
Exercise: $8.55Exp: 2033-02-01→ Class A Common Stock (0 underlying) - 348,380
Stock Option (Right to Buy)
Exercise: $10.09Exp: 2034-02-09→ Class A Common Stock (0 underlying) - 3,914
Stock Option (Right to Buy)
Exercise: $11.40From: 2022-02-04Exp: 2032-02-04→ Class A Common Stock (0 underlying)
Footnotes (8)
- [F1]Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2024.
- [F2]This transaction was executed in multiple trades at prices ranging from $7.49 to $8.01 The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]This transaction was executed in multiple trades at prices ranging from $7.31 to $7.99. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F4]The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events.
- [F5]The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter.
- [F6]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- [F7]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
- [F8]The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Documents
Issuer
RECURSION PHARMACEUTICALS, INC.
CIK 0001601830
Entity typeother
Related Parties
1- filerCIK 0001855980
Filing Metadata
- Form type
- 4
- Filed
- Nov 13, 7:00 PM ET
- Accepted
- Nov 14, 7:19 PM ET
- Size
- 21.4 KB